Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Agents. Found 204 abstracts

no pagination
Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 2001 Sep;22(9):1379-83.
Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology (Huntingt). 2000 May;14(5):719-29; discussion 729-31, 734, 737.
Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Jun;77(3):446-9.
Chu J, Gallo JM. Application of microdialysis to characterize drug disposition in tumors. Adv Drug Deliv Rev. 2000 Dec 15;45(2-3):243-53.
Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochemical pharmacology. 2000 Nov;60(9):1305-13.
Fowble B, Hanlon A, Freedman G, Nicolaou N, Hoffman J, Sigurdson E, Boraas M, Torosian M, Goldstein L. Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage I and II breast cancer. Int J Radiat Oncol Biol Phys. 2000 Jul;47(4):883-94.
Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol. 2000 Jun;18(12):2459-67.
Langer CJ. The role of new agents in advanced non-small-cell lung carcinoma. Current oncology reports. 2000 Jan;2(1):76-89.
Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. Journal of the National Cancer Institute. 2000 Dec 06;92(23):1934-40.
Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res. 2000 Oct;60(19):5390-4.
Schwartz AL, Nail LM, Chen S, Meek P, Barsevick AM, King ME, Jones LS. Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest. 2000 Jan;18(1):11-9.
Young RC. The sounds of silence. Nature. 2000 Nov 09;408(6809):141.
Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The oncologist. 1999 Jan;4(2):87-94.
Ozols RF. Oncology: current trends in the treatment of advanced ovarian cancer. Journal of Care Management. 1999 Aug;5(4):Disease Manage Digest: 6-7.
Dresler CM. Kidney metastases. Chest Surg Clin N Am. 1998 Feb;8(1):127-9.
Sokol DB, Hudes GR. Cisplatin-based chemotherapy for testicular cancer in a patient with spinal muscular atrophy: a case report. Am J Clin Oncol. 1998 Aug;21(4):420-1.
Tew KD, O'Brien M, Laing NM, Shen H. Coordinate changes in expression of protective genes in drug-resistant cells. Chem Biol Interact. 1998 Apr 24;111-112:199-211.
Fowble B. Postmastectomy radiation: then and now. Oncology (Huntingt). 1997 Feb;11(2):213-34, 239; discussion 239-40, 243.
Zhang X, Minale L, Zampella A, Smith CD. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides. Cancer Res. 1997 Sep;57(17):3751-8.
Martin V. Ovarian cancer: an update on new directions in screening and treatment. Journal of Gynecologic Oncology Nursing. 1996 Jan;6(3):9-11.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Agents

Antineoplastic Agents Human drug therapy Female US Gov't Support-PHS therapeutic use physiology metabolism pharmacology Aged Adult pathology Cisplatin Middle Age Ovarian Neoplasms drug effects Cultured Tumor Cells genetics Neoplasms Non-US Gov't Support Animal Male Paclitaxel Neoplasm Drug Resistance Phytogenic Antineoplastic Agents radiotherapy adverse effects Disease-Free Survival Topotecan antagonists & inhibitors DNA Fragmentation surgery prevention & control secondary tu [Therapeutic use] biosynthesis Breast Neoplasms Clinical Trials Local Neoplasm Recurrence 80 and over Aged enzymology Multiple Drug Resistance ad [Administration and Dosage] Neoplasm Staging Doxorubicin Lung Neoplasms Polymers dt [Drug Therapy] Prognosis Antitumor Drug Screening Assays analogs & derivatives Survival Analysis pharmacokinetics Protein-Serine-Threonine Kinases Combined Modality Therapy methods Thiotepa an [Analysis] Enzyme Activation Infiltrating Duct Carcinoma Socioeconomic Factors Treatment Outcomes Fatigue Affect Age Factors epidemiology 3T3 Cells Intravesical Administration Porifera Camptothecin Tretinoin Cytotoxins Mycobacterium bovis Spinal Muscular Atrophy Smooth Muscle-Vascular Transitional Cell Carcinoma DNA Repair Meta-Analysis Glutathione Cytochalasin B mortality Non-Small-Cell Lung Carcinoma Type II DNA Topoisomerases Cyclins Immunohistochemistry use Bladder Neoplasms Salvage Therapy Magnetic Resonance Imaging Axilla Cancer Screening Carrier Proteins Follow-Up Studies Acrylates DNA-Binding Proteins therapy Lymphatic Irradiation Enzyme-Linked Immunosorbent Assay Prospective Studies Anthracycline Antibiotics Microfilaments Menopause cytology Analysis of Variance therapeutic Radiotherapy Dosage Isoenzymes Adenosinetriphosphatase physiopathology Radiotherapy Cell Division Cell Death Cell Survival Combination Drug Therapy Testicular Neoplasms Antineoplastic Antibiotics cdc Genes Kidney Neoplasms Antineoplastic Antimetabolites Adolescent Methotrexate US Gov't Support-Non-PHS Drug Combinations Residual Neoplasm Proteins Microdialysis Thiazoles United States Interferons Antineoplastic Combined Chemotherapy Protocols Transfection Case Report Continuing (Credit) Education Cell Cycle Carboplatin Anticarcinogenic Agents Immunologic Adjuvants Adjuvant Chemotherapy Actins Vinblastine Hela Cells Quality of Life Squamous Cell Carcinoma Pyrans HT29 Cells Risk Factors Immunotherapy ultrastructure Ethacrynic Acid Phase I Clinical Trials
Last updated on Thursday, July 09, 2020